A--PREVENT IDIQ MATO RFP

The National Institutes of Health, National Cancer Institute issued solicitation 75N91023R00024 to support the PREVENT Cancer Preclinical Drug Development Program. This requirement utilizes an Indefinite Delivery/Indefinite Quantity Multiple Award Task Order contract vehicle to provide preclinical efficacy and intermediate endpoint biomarkers, preclinical services for biopharmaceutical product development and manufacturing, and toxicology and pharmacology testing. The scope of work focuses on advancing cancer prevention research through specialized drug development and manufacturing services.

The acquisition is categorized under NAICS 541714: Research and Development in Biotechnology (except Nanobiotechnology) and PSC AN12: HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH. Proposals were due by February 28, 2023, with Richard Taylor serving as the primary point of contact. The solicitation has been updated through multiple amendments, including Amendment 02 which introduced minor changes to the program requirements and issued revised attachments for the preclinical services and testing protocols.

Documentation for this opportunity includes 14 attachments, such as multiple solicitation amendments, revised exhibits, and a questions and answers document. These materials detail the requirements for the PREVENT program’s preclinical services and product manufacturing components. The notice and its associated files were last updated on September 16, 2024, to reflect the final solicitation status and historical record of the procurement process.